Liberate Medical Closes $6.2M Series B Financing

Liberate Medical has closed $6.2 million series B financing co-led by a large strategic investor and Scientific Health Development, both of whom will join Liberate Medical’s Board to solidify Liberate Medical’s position as a leading innovator in respiratory and critical care.

Liberate Medical’s VentFree Respiratory Muscle Stimulator is the only non-invasive, breath synchronized, neuromuscular electrical stimulator intended to prevent expiratory muscle atrophy in mechanically ventilated patients.

A key focus of the funding will be to support the pivotal clinical trial of VentFree, known as the PREVENT trial, aiming to demonstrate that VentFree reduces the duration of invasive mechanical ventilation in patients that are at risk of being difficult to wean.

Reducing the time patients spend on mechanical ventilation may reduce the risks of prolonged mechanical ventilation, including hospital acquired infections, deteriorated quality of life and death. The Series B funding will provide the necessary resources to complete the PREVENT trial, in anticipation of FDA regulatory clearance and full commercial launch of VentFree.

The PREVENT trial follows two successful pilot randomized controlled trials that were completed in Europe and Australia. VentFree has FDA Breakthrough Device Designation, FDA Emergency Use Authorization and CE marking in the European Union.

“We are thrilled to have Scientific Health Development and our strategic partner join us as co-leads in this Series B financing round,” said Angus McLachlan, CEO of Liberate Medical. “Their support and expertise will be instrumental as we conduct the PREVENT trial and prepare for full commercialization of VentFree.”